GUARDIAN registry data was analyzed to evaluate post-operative cost differences from improvements in clinical outcomes and their associated reductions in clinical interventions1
1) Voight et al., ASAIO Journal 2022
Improved 2-Year Heart Transplant Survival with Moderate Hypothermic Donor Heart Preservation
S. Silvestry, D. Meyer, S. Pham, J. Jacobs, Y. Shudo, J. Schroder, M. Leacche, C. Sciortino, H. Copeland, M. Rodrigo, K. Takeda, M. Kawabori, B. Mahesh, L. Klein, A. Vidic, S. Patel, D. D’Alessandro
ISHLT 2024 Presentation
Investigators found that 2-year post transplant survival in matched cohorts (from 89% to 95%, p=0.04) is superior in the SherpaPak cohort1. This survival benefit is potentially due to reduced the incidence of severe PGD (from 11% vs 5.5%, p=0.01) and reduced need for mechanical circulatory support after transplant1. The study concluded that Advanced hypothermic preservation of the donor heart should be strongly considered as an important factor contributing to a center’s post transplant and 2-year outcomes.1
1) Silvestry et al., ISHLT Presentation 2024, Data on file
Comparison of Paragonix SherpaPak to Ice Storage, Paragonix data on file. GUARDIAN is a registered clinical study (NCT04141605) funded and administered by Paragonix Technologies. The data from the registry is descriptive, not statistically powered, and not pre-specified. The information should be interpreted accordingly.